The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Open accessAbstract
To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group received IFN β-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-μg/ml (12 million IU/ml) dose of interferon β-1a was subcutaneously injected three times weekly for two consecutive weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · cited 1×
“Total scores of 8, 5 to 8, and 1 to 4 were considered definite, probable, and possible correlations between the use of IFN and the adverse drug reaction, respectively (51).”
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014
A novel coronavirus outbreak of global health concern
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
WHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 3,806
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202001-0179le · Cited by 916
Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · doi:10.1101/2020.01.26.919985 · Cited by 860
Clinical course and mortality risk of severe COVID-19
Weiss, P., & Murdoch, D. R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30633-4 · Cited by 688
Kopecky-Bromberg, S. A., Martínez-Sobrido, L., Frieman, M., Baric, R. A., & Palese, P. (2007) · Journal of Virology · doi:10.1128/jvi.01782-06 · Cited by 673
Comorbidities and multi-organ injuries in the treatment of COVID-19
Wang, T., Du, Z., Zhu, F., Cao, Z., An, Y., Gao, Y., & Jiang, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30558-4 · Cited by 632
Sex difference and smoking predisposition in patients with COVID-19
Cai, H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30117-x · Cited by 625
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S. A., Palese, P., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.01012-07 · Cited by 507
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
Treatment of SARS with human interferons
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13973-6 · Cited by 467
Interferon-α2b Treatment for COVID-19
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01061 · Cited by 417
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
COVID-19: towards understanding of pathogenesis
Cao, W., & Li, T. (2020) · Cell Research · doi:10.1038/s41422-020-0327-4 · Cited by 344
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
Roback, J. D., & Guarner, J. (2020) · JAMA · doi:10.1001/jama.2020.4940 · Cited by 299
Treatment of COVID-19: old tricks for new challenges
Cunningham, A. C., Goh, H. P., & Koh, D. (2020) · Critical Care · doi:10.1186/s13054-020-2818-6 · Cited by 286
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
Zhang, S., Li, L., Shen, A., Chen, Y., & Qi, Z. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00917-3 · Cited by 212
Hart, B. J., Dyall, J., Postnikova, E., Zhou, H., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Frieman, M. B., Holbrook, M. R., Jahrling, P. B., et al. (2014) · Journal of General Virology · doi:10.1099/vir.0.061911-0 · Cited by 211
Rethinking the role of hydroxychloroquine in the treatment of COVID‐19
Meyerowitz, E. A., Vannier, A. G. L., Friesen, M. G. N., Schoenfeld, S., Gelfand, J. A., Callahan, M. V., Kim, A. Y., Reeves, P. M., & Poznansky, M. C. (2020) · The FASEB Journal · doi:10.1096/fj.202000919 · Cited by 175
Bellingan, G. J., Maksimow, M., Howell, D. C. J., Stotz, M., Beale, R. J., Beatty, M., Walsh, T. S., Binning, A. R., Davidson, A., Kuper, M., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70259-5 · Cited by 148
The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition
Flammer, J. R., Dobrovolná, J., Kennedy, M. A., Chinenov, Y. V., Glass, C. K., Ivashkiv, L. B., & Rogatsky, I. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00146-10 · Cited by 135
Ranieri, V. M., Pettilä, V., Karvonen, M. K., Jalkanen, J. M., Nightingale, P., Brealey, D. A., Mancebo, J., Ferrer, R., Mercat, A., Patroniti, N. A., et al. (2020) · JAMA · doi:10.1001/jama.2019.22525 · Cited by 132
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
Hu, X. S., Miller, L., Richman, S., Hitchman, S., Glick, G., Liu, S., Zhu, Y., Crossman, M., Nestorov, I. A., Gronke, R. S., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407068 · Cited by 119
Acquired Liver Injury in the Intensive Care Unit
Lescot, T., Karvellas, C. J., Beaussier, M., Magder, S. A., & Riou, B. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318266c6df · Cited by 118
Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons
Scagnolari, C., Vicenzi, E., Bellomi, F., Stillitano, M. G., Pinna, D., Poli, G., Clementi, M., DIANZANI, F., & Antonelli, G. (2004) · Antiviral Therapy · doi:10.1177/135965350400900618 · Cited by 87
Xu, C., Zheng, F., Qing, Y., Ding, S., Yang, D., Lei, C., Yin, Z., Zhou, X., Jiang, D., Zuo, Q., et al. (2020) · medRxiv · doi:10.1101/2020.03.03.20030353 · Cited by 78
Peterson, R. L., Vock, D. M., Powers, J. H., Emery, S., de la Cruz, E., Hunsberger, S., Jain, M. K., Pett, S. L., Neaton, J. D., & for the INSIGHT FLU-IVIG Study Group (2017) · Clinical Trials · doi:10.1177/1740774517697919 · Cited by 33
A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2
Su, S., & Jiang, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0185-z · Cited by 24
Cited by
Risk factors for severe and critically ill COVID‐19 patients: A review
Gao, Y., Ding, M., Dong, X., Zhang, J., Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y., Fu, W., Li, W., et al. (2021) · Allergy · doi:10.1111/all.14657 · Cited by 1,402
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Pathophysiology of COVID-19-associated acute kidney injury
Legrand, M., Bell, S., Forni, L., Joannidis, M., Koyner, J. L., Liu, K., & Cantaluppi, V. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00452-0 · Cited by 500
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
Karki, R., Lee, S., Mall, R., Pandian, N., Wang, Y., Sharma, B. R., Malireddi, R. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 350
Metadata
- Authors
- Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-08-20
- Volume
- 64
- Issue
- 9
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W3043399375
- Cited by
- 306
- References
- 53
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.